Phase Genomics Advances Precision Oncology with OncoTerraa New Ultra-Long-Range Sequencing Powered Platform

Phase Genomics announces OncoTerra™, its new research use only (RUO) cancer genomics platform leveraging ultra-long-range sequencing technology

SEATTLE--()--Phase Genomics, Inc., a biotech company leading advancements in next-generation sequencing (NGS) solutions for genome assembly and analysis, today announced the launch of its new platform for precision oncology.

The OncoTerra platform implements a rapid, cost-effective alternative to current cytogenomic analysis tools while unlocking information in even the most challenging of sample types. The platform offers genome-wide detection of a wide range of chromosomal abnormalities without the need for actively dividing cells, high molecular weight DNA extraction, or a high starting cell volume—all in a single assay. Furthermore, it is most uniquely effective on formalin-fixed paraffin-embedded (FFPE) samples, enabling a host of new oncology applications.

“Capturing structural genomic information in previously inaccessible sample types and transforming it into actionable insights relevant to human health is an immensely powerful capability of our technology,” said Ivan Liachko, Founder and CEO of Phase Genomics. “Accessing the vast amounts of clinical information that has been locked away in FFPE samples will be of great use to translational researchers in the oncology space.”

FFPE samples currently make up >90% of samples from biopsies, or over 2 billion samples. The OncoTerra platform offers the unique capacity to unlock cytogenomic information stored in these samples, allowing researchers to collect more data than ever before, potentially leading to advancements in clinical care and diagnostics.

The platform is powered by Phase Genomics’ ultra-long-range sequencing technology that captures physical proximity data from DNA sequences in the genome. These data are then analyzed via proprietary machine learning tools to detect diverse chromosomal aberrations and rearrangements, including tumorigenic rearrangements, that cause and characterize diseases.

The Phase Genomics platform is for research use only and is not for use in diagnostic procedures. More information on the platform is available here.

View a webinar, hosted by Phase Genomics to learn more about this technology and follow Phase Genomics on Twitter for the latest news and information.


Phase Genomics applies Hi-C and other proximity-ligation methods to enable chromosome-scale genome assembly, metagenomic deconvolution, as well as analysis of structural genomic variation and genome architecture. They offer a comprehensive portfolio of laboratory and computational services and products, including Hi-C kits for plants, animals, microbes, and human samples as well as industry-leading genome and metagenome assembly and analysis software.

Based in Seattle, WA, the company was founded in 2015 by a team of genome scientists, software engineers, and entrepreneurs. The company’s mission is to empower scientists with genomic tools that accelerate breakthrough discoveries.


Eric Schudiske (

Release Summary

Phase Genomics, Inc. today announced the launch of its new platform for precision oncology.


Social Media Profiles


Eric Schudiske (